foxo4-dri peptide senolytic human trial Frontiers Targeted Apoptosis of Senescent Cells

It is recommended to conduct a comprehensive evaluation before, during (day 3), and after (day 7) treatment

Phase 2 Side-Effect Frequencies at 4.5 mg/week (Lancet 2021) Side Effect Nausea Incidence at 4.5 mg/week 47% Side Effect Injection-site reactions Incidence at 4.5 mg/week 43% Side Effect Constipation Incidence at 4.5 mg/week 21% Side Effect Fatigue Incidence at 4.5 mg/week 20% Side Effect Allergic reactions (any) Incidence at 4.5 mg/week 10% Side Effect Vomiting Incidence at 4.5 mg/week 8% Side Effect Loose stools Incidence at 4.5 mg/week 7% Side Effect Headache Incidence at 4.5 mg/week 7% Side Effect Indigestion Incidence at 4.5 mg/week 4% Incidence was lower at lower doses

Federal Register FDA

"BPC 157 and standard angiogenic growth factors: effect on angiogenesis in healing." Eur J Pharmacol

Patients who are pregnant, nursing, under 18, or have active malignancies shouldn't use this combination